Skip to main content

Table 3 Treatment effect of immune checkpoint inhibitors after pemetrexed treatment failure

From: High lymphocyte population-related predictive factors for a long-term response in non-small cell lung cancer patients treated with pemetrexed: a retrospective observational study

Efficacy

Long-term

administration

( n = 11)

Intermediate-term

administration

( n = 16)

Short-term

administration

( n = 55)

Cycles

6.1 ± 8.5

5.6 ± 3.2

6.2 ± 8.3

PFS (month)

5.5 ± 6.9

3.8 ± 2.7

3.4 ± 4.4

  1. Data are presented as mean ± SD
  2. PFS progression free survival